Keri Seitz, the former CEO of FHC Inc., said she is excited to lead global sales for Biovation and help grow the company after recently joining the Boothbay-based manufacturing and bioscience company's executive management team.
Anania & Associates Investment Company LLC, a Windham-based private equity firm that owns Biovation and other manufacturing companies, announced that Seitz was recently named the company's vice president of sales and customer relations.
"I am incredibly excited that Keri has joined our team and will lead our tactical and strategic global sales efforts," Kerem Durdag, Biovation's CEO, said in a prepared statement. "During the last several years we have engaged with customers who are leaders in their market sectors, and now plan to leverage those relationships and applicable products to the larger marketplace."
He added: "Keri is the right person to lead us in our next stage of growth given her deep experience in delivering rapid revenue growth and increasing market share through highly effective results-oriented sales practices."
Seitz was named to Mainebiz's Next List in 2012 for her leadership as CEO of Bowdoin-based FHC, a maker of precision instruments and devices for brain surgery, for which she helped grow revenue by nearly 40% and quadruple the company's net operating profit.
Seitz told Mainebiz in a phone interview on Wednesday that she decided to leave FHC last August. "FHC is a great organization with wonderful products and people and I really enjoyed them," she said. "I just felt it was time for me to find something new, and I know they have a great team to [move themselves] forward."
At Biovation, Seitz will be tasked with growing and managing the company's sales organization, along with leading its partner and distributor network and following through with its growth plans.
"They have some really amazing technology," Seitz said of Biovation, which makes nonwoven fiber products with advanced polylactic acid, or PLA, for packaging, infection control, advanced wound care, hygiene and other specialty applications.
She said her current focus is promoting global sales of Biovation's BioArmour Blood Pressure Cuff Shield, a medical device that has been cleared for distribution in Europe and is currently awaiting approval by the U.S. Food and Drug Administration for domestic sales, expected to begin this year. The product is meant to help prevent the transmission of bacteria by preventing direct contact between a patient's skin with a blood pressure cuff.
Seitz said she is also working on the development of other product lines, including DryRight, a boot-drying product, also made with PLA, that is being tested by the U.S. Marine Corps under a $978,000 contract. The product is now being prepared for the commercial market, she said.
"This technology [PLA] has a lot of applications across many different business functions and markets," she said. "It feels like the sky is the limit."